keyword
MENU ▼
Read by QxMD icon Read
search

Carmustine

keyword
https://www.readbyqxmd.com/read/29330390/freezing-the-graft-is-not-necessary-for-autotransplants-for-plasma-cell-myeloma-and-lymphomas
#1
Amado Kardduss-Urueta, Robert Peter Gale, César H Gutierrez-Aguirre, Miguel Angel Herrera-Rojas, Iván Murrieta-Álvarez, Rosendo Perez-Fontalvo, Guillermo J Ruiz-Delgado, Giovanni Ruiz-Rojas, Gregorio Jaimovich, Leonardo Feldman, Nancy Labastida-Mercado, Alicia Endara, Martín Castro, Samantha Galindo-Becerra, María Angélica Cardona-Molina, David Gomez-Almaguer, Guillermo J Ruiz-Argüelles
We studied rates of granulocyte and platelets recovery in 359 consecutive subjects receiving blood cell infusions in the context of autotransplants for plasma cell myeloma (N = 216) and lymphomas (N = 143). Blood cells were mobilised with filgrastim given for 4-5 days and collected after a median of 2 (range, 1-2) apheresis. Apheresis products were stored at 4° C for a median of 3 days (range, 2-6 days). Most subjects received carmustine, etoposide, cytarabine and melphalan (BEAM), cyclophosphamide, carmustine and etoposide (CBV) or high-dose melphalan...
January 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29322918/a-linear-programming-computational-framework-integrates-phosphor-proteomics-and-prior-knowledge-to-predict-drug-efficacy
#2
Zhiwei Ji, Bing Wang, Ke Yan, Ligang Dong, Guanmin Meng, Lei Shi
BACKGROUND: In recent years, the integration of 'omics' technologies, high performance computation, and mathematical modeling of biological processes marks that the systems biology has started to fundamentally impact the way of approaching drug discovery. The LINCS public data warehouse provides detailed information about cell responses with various genetic and environmental stressors. It can be greatly helpful in developing new drugs and therapeutics, as well as improving the situations of lacking effective drugs, drug resistance and relapse in cancer therapies, etc...
December 21, 2017: BMC Systems Biology
https://www.readbyqxmd.com/read/29285355/glioblastoma-fed-by-middle-meningeal-artery-and-displaying-cyst-formation-soon-after-repeated-implantation-of-carmustine-wafers-a-case-report
#3
Shun Yamamuro, Yuya Hanashima, Sodai Yoshimura, Hiroyuki Aoki, Koki Kamiya, Yusuke Takamine, Hiroshi Negishi, Atsuo Yoshino
The present study reported an unusual case of temporal lobe glioblastoma (GBM) fed from the middle meningeal artery that progressed rapidly. A 66-year-old male was admitted to the Department of Neurosurgery at Nihon University Itabashi Hosipital (Tokyo, Japan) with epilepsy. Magnetic resonance imaging disclosed a small well-enhanced right middle fossa mass lesion, which was relatively boundary-clear and attached to the dura mater. An angiogram showed a stain fed from the right middle meningeal artery. The mass lesion was removed completely by surgery and diagnosed pathologically as GBM...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29274437/convection-enhanced-delivery-of-chemotherapeutic-drugs-into-brain-tumour
#4
Wenbo Zhan, Chi-Hwa Wang
Convection enhanced delivery (CED) of chemotherapeutic drugs can successfully bypass the blood-brain barrier (BBB). However, the treatment efficacy is significantly variable in clinic owing to the absence of proper drugs and the lack of understanding on the local drug transport. In this study, mathematical modelling is employed to investigate the suitability of six chemotherapeutic drugs from the perspective of intratumoural transport, including fluorouracil, carmustine, cisplatin, methotrexate, doxorubicin and paclitaxel...
December 20, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29228450/mir-21-enhanced-glioma-cells-resistance-to-carmustine-via-decreasing-spry2-expression
#5
G-B Wang, J-H Liu, J Hu, K Xue
OBJECTIVE: Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance. miR-21 is a vital oncogenic miRNA that regulates drug resistance of tumor cells. This study aims to elucidate the function of miR-21 in human glioma cells resistant to carmustine (BCNU) and to demonstrate the underlying molecular mechanism. MATERIALS AND METHODS: BCNU-sensitive cells (SWOZ2 cells) were transfected with miR-21 agomir and negative control, and BCNU-resistance cells (SWOZ2-BCNU cells) were transfected with miR-21 antagomir and negative control...
November 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29228449/igfbp2-induces-spry1-expression-via-nf-%C3%AE%C2%BAb-signaling-pathway-in-glioblastoma-multiforme-gbm
#6
Z-S Yuan, Y Cao, Z-Y Li
OBJECTIVE: Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance. miR-21 is a vital oncogenic miRNA that regulates drug resistance of tumor cells. This study aims to elucidate the function of miR-21 in human glioma cells resistant to carmustine (BCNU) and to demonstrate the underlying molecular mechanism. MATERIALS AND METHODS: BCNU-sensitive cells (SWOZ2 cells) were transfected with miR-21 agomir and negative control, and BCNU-resistance cells (SWOZ2-BCNU cells) were transfected with miR-21 antagomir and negative control...
November 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29213063/efficacy-and-safety-of-hd-mtx-based-systemic-chemotherapy-regimens-retrospective-study-of-induction-therapy-for-primary-central-nervous-system-lymphoma-in-chinese
#7
Xiao Han, Yali Ji, Mingqi Ouyang, Tienan Zhu, Daobin Zhou
We performed a retrospective study of 49 patients with newly diagnosed primary central nervous system lymphoma (PCNSL), to compare the efficacy and safety of different high-dose methotrexate (HD-MTX) based systemic chemotherapy regimens as induction therapy. 25 patients received AB ± R alternative regimen (consist methotrexate, ifosfamide, vindesine, dexamethasone, carmustine and teniposide), while others received HD-MTX ± R regimen. The complete response rate and overall response rate of AB ± R group and HD-MTX ± R group were 36...
December 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29206049/rationale-and-design-of-the-500-patient-3-year-and-prospective-vigilant-observation-of-gliadel-wafer-implant-registry
#8
Kevin O Lillehei, Steven N Kalkanis, Linda M Liau, Dellann Elliott Mydland, Jeffrey Olson, Nina A Paleologos, Timothy Ryken, Tania Johnson, Evan Scullin
Implantation of biodegradable wafers impregnated with carmustine (BCNU) is one of the few chemotherapeutic modalities that have been evaluated in Phase III trials and approved by the US FDA for treatment of newly diagnosed high-grade glioma and recurrent glioblastoma. Enrolling up to 500 patients for 3-year follow-up at over 30 sites, the prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) registry (NCT02684838) will evaluate BCNU wafers for treatment of CNS malignancies in contemporary practice and in the new era of molecular tumor analysis...
December 5, 2017: CNS Oncology
https://www.readbyqxmd.com/read/29199519/outcomes-of-da-epoch-r-induction-plus-autologous-transplant-consolidation-for-double-hit-lymphoma
#9
Andy I Chen, Jessica T Leonard, Craig Y Okada, Nathan D Gay, Kari Chansky, Guang Fan, Jennifer B Dunlap, Philipp W Raess, Rita M Braziel, Alex Stentz, Richard T Maziarz
High-grade B cell lymphoma with MYC and BCL2 rearrangements (double hit) has a poor prognosis with standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). We report here a treatment algorithm of DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) followed by BEAM (carmustine, etoposide, cytarabine, melphalan) autologous transplant in 36 cases of previously untreated double hit lymphoma (DHL) from 2010 to 2015. A high risk International Prognostic Index (IPI) was present in 42% of cases...
December 3, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164977/a-retrospective-matched-paired-analysis-comparing-bendamustine-containing-beeam-versus-beam-conditioning-regimen-results-from-a-single-center-experience
#10
Khalil Saleh, Alina Danu, Serge Koscielny, Clémence Legoupil, Sylvain Pilorge, Cristina Castilla-Llorente, David Ghez, Julien Lazarovici, Jean-Marie Michot, Nadine Khalife-Saleh, Valerie Lapierre, Kamelia Alenxandrova, Julia Arfi-Rouche, Jean-Henri Bourhis, Vincent Ribrag
The combination of carmustine, etoposide, aracytin, and melphalan(BEAM) conditioning regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. It is also an option in patients with very-high risk aggressive NHL in first complete remission (CR). Recently, a phase Ib-II feasibility study using bendamustine replacing carmustine (BCNU) was reported. We report herein a safety and efficacy analysis of bendamustine-EAM (BeEAM) with a control BEAM counterpart paired cohort (1/2)...
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29164054/effective-drug-delivery-in-diffuse-intrinsic-pontine-glioma-a-theoretical-model-to-identify-potential-candidates
#11
Fatma E El-Khouly, Dannis G van Vuurden, Thom Stroink, Esther Hulleman, Gertjan J L Kaspers, N Harry Hendrikse, Sophie E M Veldhuijzen van Zanten
Despite decades of clinical trials for diffuse intrinsic pontine glioma (DIPG), patient survival does not exceed 10% at two years post-diagnosis. Lack of benefit from systemic chemotherapy may be attributed to an intact bloodbrain barrier (BBB). We aim to develop a theoretical model including relevant physicochemical properties in order to review whether applied chemotherapeutics are suitable for passive diffusion through an intact BBB or whether local administration via convection-enhanced delivery (CED) may increase their therapeutic potential...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29156646/inhibition-of-bcl-2-and-cox-2-protein-expression-after-local-application-of-a-new-carmustine-loaded-clinoptilolite-based-delivery-system-in-a-chemically-induced-skin-cancer-model-in-mice
#12
Cristina Mihaela Ghiciuc, Aurel Lulu Strat, Lacramioara Ochiuz, Catalina Elena Lupusoru, Maria Ignat, Aurelia Vasile, Alexandru Grigorovici, Iulian Stoleriu, Carmen Solcan
Our research has focused on in vitro and in vivo evaluations of a new Carmustine (BCNU)-loaded clinoptilolite-based delivery system. Two clinoptilolite ionic forms-hydrogen form (HCLI) and sodium form (NaCLI)-were prepared, allowing a loading degree of about 5-6 mg BCNU/g of zeolite matrix due to the dual porous feature of clinoptilolite. Clinoptilolite-based delivery systems released 35.23% of the load in 12 h for the BCNU@HCLI system and only 10.82% for the BCNU@NaCLI system. The BCNU@HCLI system was chosen to develop gel and cream semisolid dosage forms...
November 20, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/29139095/local-alkylating-chemotherapy-applied-immediately-after-5-ala-guided-resection-of-glioblastoma-does-not-provide-additional-benefit
#13
William Sage, Mathew Guilfoyle, Catriona Luney, Adam Young, Rohitashwa Sinha, Donatella Sgubin, Joseph H McAbee, Ruichong Ma, Sarah Jefferies, Rajesh Jena, Fiona Harris, Kieren Allinson, Tomasz Matys, Wendi Qian, Thomas Santarius, Stephen Price, Colin Watts
Grade IV glioma is the most common and aggressive primary brain tumour. Gross total resection with 5-aminolevulinic acid (5-ALA) guided surgery combined with local chemotherapy (carmustine wafers) is an attractive treatment strategy in these patients. No previous studies have examined the benefit carmustine wafers in a treatment programme of 5-ALA guided resection followed by a temozolomide-based chemoradiotherapy protocol. The objective of this study was to examine the benefit of carmustine wafers on survival in patients undergoing 5-ALA guided resection...
November 14, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29122306/carmustine-wafer-implantation-for-high-grade-gliomas-evidence-based-safety-efficacy-and-practical-recommendations-from-the-neuro-oncology-club-of-the-french-society-of-neurosurgery
#14
REVIEW
A Roux, F Caire, J Guyotat, P Menei, P Metellus, J Pallud
There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation). Compelling clinical data also support the safety of carmustine wafer implantation (grade A recommendation) in these patients and suggest that observed adverse events can be avoided in experienced neurosurgeon hands...
December 2017: Neuro-Chirurgie
https://www.readbyqxmd.com/read/29084203/high-dose-bcnu-melphalan-conditioning-regimen-before-autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma
#15
D Sivaraj, W Bacon, G D Long, D A Rizzieri, M E Horwitz, K M Sullivan, Y Kang, Z Li, N J Chao, C Gasparetto
Single-agent high-dose melphalan (HDM, 200 mg/m(2)) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its introduction in 1992. We used a more aggressive alkylator-based conditioning regimen in an attempt to overcome early relapse and combat drug resistance. We present a retrospective comparison and long-term follow-up of newly diagnosed patients with multiple myeloma (MM) treated with induction followed by either high-dose carmustine (BCNU) and HDM, or HDM alone, both followed by autologous stem cell transplant (ASCT)...
October 30, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29081442/glioblastoma-treatment-in-the-elderly
#16
Masaki Okada, Keisuke Miyake, Takashi Tamiya
Although current treatment advances prolong patient survival, treatment for glioblastoma (GBM) in the elderly has become an emerging issue. The definition of "elderly" differs across articles; GBM predominantly occurs at an age ≥65 years, and the prognosis worsens with increasing age. Regarding molecular markers, isocitrate dehydrogenase (IDH) mutations are less common in the elderly with GBM. Meanwhile, O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation has been identified in approximately half of patients with GBM...
October 30, 2017: Neurologia Medico-chirurgica
https://www.readbyqxmd.com/read/29061536/total-body-irradiation-is-safe-and-similarly-effective-to-chemotherapy-only-conditioning-in-autologous-stem-cell-transplantation-for-mantle-cell-lymphoma-patients
#17
Yolanda D Tseng, Philip A Stevenson, Ryan D Cassaday, Andrew Cowan, Brian G Till, Mazyar Shadman, Solomon A Graf, Ralph Ermoian, Stephen D Smith, Leona A Holmberg, Oliver W Press, Ajay K Gopal
Autologous stem cell transplant (ASCT) consolidation has become a standard approach for patients with mantle cell lymphoma (MCL), yet there is little consensus on the role of total body irradiation (TBI) as part of high-dose transplant conditioning. We analyzed 75 consecutive MCL patients that underwent ASCT at our institution between 2001-2011 with either TBI-based (n=43) or carmustine, etoposide, cytarabine, melphalan (n=32; BEAM) high-dose conditioning. Most patients (97%) had chemosensitive disease and were transplanted in first remission (89%)...
October 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29054815/whole-brain-radiotherapy-or-autologous-stem-cell-transplantation-as-consolidation-strategies-after-high-dose-methotrexate-based-chemoimmunotherapy-in-patients-with-primary-cns-lymphoma-results-of-the-second-randomisation-of-the-international-extranodal-lymphoma
#18
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P Fox, Elisabeth Schorb, Paul La Rosée, Mascha Binder, Alberto Fabbri, Valter Torri, Eleonora Minacapelli, Monica Falautano, Fiorella Ilariucci, Achille Ambrosetti, Alexander Roth, Claire Hemmaway, Peter Johnson, Kim M Linton, Tobias Pukrop, Jette Sønderskov Gørløv, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jens Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Alessandro Levis, Stefan W Krause, Hans J Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, Francesco Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus
BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested...
November 2017: Lancet Haematology
https://www.readbyqxmd.com/read/29052026/high-dose-chemotherapy-and-autologous-peripheral-blood-stem-cell-transplantation-with-bcvac-regimen-followed-by-maintenance-chemotherapy-for-children-with-very-high-risk-acute-lymphoblastic-leukemia
#19
Che Ry Hong, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn
Allogeneic hematopoietic stem cell transplantation (HSCT) is the recommended treatment for children with very high risk acute lymphoblastic leukemia (ALL), but it requires adequate institutional infrastructure, experience, and expertise, especially for alternative donor HSCT. We review our experience with high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (APBSCT), followed by post-APBSCT maintenance chemotherapy for children with very high risk ALL. Between August 1997 and November 2012, our institute was not successful with HLA-haploidentical HSCT...
October 20, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/29035395/replacing-carmustine-by-thiotepa-and-cyclophosphamide-for-autologous-stem-cell-transplantation-in-hodgkin-s-and-non-hodgkin-s-b-cell-lymphoma
#20
E Joffe, D Rosenberg, U Rozovski, C Perry, I Kirgner, S Trestman, O Gur, F Aviv, N Sarid, A Kolomansky, L Gepstein, Y Herishanu, E Naparstek
This study aimed to compare the real-life results of TECAM, a thiotepa-based conditioning regimen consisting of thiotepa (40 mg/m2 days -5 to -2), etoposide (200 mg/m2 days -6 to -3), cytarabine (200 mg/m2 days -4 to -1), cyclophosphamide (60 mg/kg day -3), and melphalan (60 mg/m2 days -2 to -1) with that of the conventional carmustine-based regimen BEAM. We reviewed 125 consecutive patients who underwent a first autologous transplantation (ASCT) for B-cell lymphomas at a large tertiary transplantation center between 1999 and 2014...
January 2018: Bone Marrow Transplantation
keyword
keyword
56059
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"